Your new experience awaits. Try the new design now and help us make it even better

STUDY PROTOCOL article

Front. Public Health

Sec. Infectious Diseases: Epidemiology and Prevention

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1668926

This article is part of the Research TopicWorld TB Day 2025: Yes! We Can End TB: Commit, Invest, DeliverView all 6 articles

Consolidation of a Genomic Epidemiological Surveillance Network for Tuberculosis (REVIGET) in Northern and Northeastern Brazil: A Study Protocol

Provisionally accepted
Emilyn  Costa ConceiçãoEmilyn Costa Conceição1,2,3*Karla  Valéria Batista LimaKarla Valéria Batista Lima4,5Cristiane  Cunha FrotaCristiane Cunha Frota6Theolis  BarbosaTheolis Barbosa3,7Adriana  Ayden FerreiraAdriana Ayden Ferreira8Abhinav  SharmaAbhinav Sharma1Davi  Josué MarconDavi Josué Marcon4,5Layana  Rufino RibeiroLayana Rufino Ribeiro4,9Alex  Brito SouzaAlex Brito Souza4,5Danna  Karen Correa dos SantosDanna Karen Correa dos Santos4,5Carlos  Augusto Abreu AlberioCarlos Augusto Abreu Alberio10Ricardo  Jose de Paula Souza e GuimaraesRicardo Jose de Paula Souza e Guimaraes11,9Ismari  Perini FurlanetoIsmari Perini Furlaneto12Lilian  Eduarda De Oliveira FreitasLilian Eduarda De Oliveira Freitas8Emmily  Oliveira AmadorEmmily Oliveira Amador4,5Hendor  Neves Ribeiro De JesusHendor Neves Ribeiro De Jesus7Barreto  LBPFBarreto LBPF13Maria Cristina  da Silva LourencoMaria Cristina da Silva Lourenco13Tulio  De OliveiraTulio De Oliveira2Robin  Mark WarrenRobin Mark Warren1
  • 1DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; SAMRC Centre for Tuberculosis Research; Division of MBHG, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
  • 2Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
  • 3Rede Brasileira de Pesquisas em Tuberculose, Rio de Janeiro, Brazil
  • 4Secao de Bacteriologia, Instituto Evandro Chagas, Ananindeua, Brazil
  • 5Programa de Pos-graduacao em Biologia Parasitária na Amazonia, Universidade do Estado do Para, Belém, Brazil
  • 6Universidade Federal do Ceara, Programa de Pos-graduacao em Patologia, Fortaleza, Brazil
  • 7Instituto Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, Brazil
  • 8Laboratorio Central do Amazonas, Fundacao de Vigilancia em Saude do Amazonas Dra Rosemary Costa Pinto, Manaus, Brazil
  • 9Programa de Pos-graduacao em Epidemiologia e Vigilancia em Saude, Instituto Evandro Chagas, Ananindeua, Brazil
  • 10Hospital Universitário Joao de Barros Barreto da Universidade Federal do Para, Belem, Brazil
  • 11Geoprocessamento, Instituto Evandro Chagas, Ananindeua, Brazil
  • 12Centro Universitario do Para, Belem, Brazil
  • 13Laboratorio de Bacteriologia e Bioensaios em Micobacterias, Instituto Nacional de Infectologia Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil

The final, formatted version of the article will be published soon.

Globally, tuberculosis (TB) remains a top cause of death from infectious diseases, with an estimated 1.5 million deaths annually. Given its substantial social and economic burden, TB is a priority in the United Nations 2030 Agenda for Sustainable Development. The WHO's End TB Strategy emphasizes research, innovation, and the rapid implementation of new technologies, such as whole-genome sequencing (WGS), which are pivotal for precision health approaches and drug-resistant TB (DR-TB) surveillance. This study aims to strengthen genomic TB surveillance in the North and Northeast Brazilian regions by applying WGS to study DR-TB cases, training professionals in genomics and bioinformatics, and deploying a national surveillance platform (GEMIBRA). This is an observational, cross-sectional, prospective, quantitative, and qualitative study to be conducted in the states of Pará, Amazonas, Ceará, and Bahia. A total of 500 Mycobacterium tuberculosis complex (MTBC) isolates from DR-TB cases will undergo whole-genome sequencing (WGS), representing 87% of the expected DR-TB cases, including non-tuberculous mycobacteria (NTM) isolates among the DR samples. Data will be analyzed for genotype-phenotype correlations, mutation patterns, and associations with clinical and epidemiological characteristics. Capacity-building activities, including theoretical and hands-on bioinformatics training, will be carried out. The GEMIBRA platform will support data visualization, spatial distribution, and clinical decision-making. The project will generate evidence to validate the contribution of WGS integration in Brazil's TB surveillance system, support precision treatment approaches, and inform public health interventions. It will also contribute to workforce development and the introduction of decentralized WGS-based diagnostics in resource-limited regions. The project adopts a translational research model and a networked, decentralised approach, facilitating the prompt integration of the knowledge generated into public health practice. Ultimately, this work will contribute to combating TB transmission by identifying transmission dynamics,

Keywords: Drug-resistant tuberculosis, Genomic surveillance, Whole-genome sequencing, Capacity Building, Brazil

Received: 18 Jul 2025; Accepted: 29 Sep 2025.

Copyright: © 2025 Conceição, Lima, Frota, Barbosa, Ferreira, Sharma, Marcon, Ribeiro, Souza, dos Santos, Alberio, Guimaraes, Furlaneto, De Oliveira Freitas, Amador, Neves Ribeiro De Jesus, LBPF, Lourenco, De Oliveira and Warren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Emilyn Costa Conceição, emilyncosta@sun.ac.za

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.